Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc Ord (OP:AZNCF)

181.23 +0.69 (+0.38%)
Streaming Delayed Price Updated: 12:16 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc Ord

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
AstraZeneca Stock Gains As Q2 Earnings Beat Forecasts, Clocks $894M In COVID-19 Vaccine Sales ↗
AstraZeneca plc (NASDAQ: AZN) COVID vaccine generated $894 million in sales in Q2. The group added that it shipped about 319 million doses worldwide during 1H of 2021,... 
Via Benzinga
Topics Earnings
News headline image
EMA's CHMP Backs AstraZeneca's Drug For Rare Blood Disorder In Children ↗
AstraZeneca Plc (NASDAQ: AZN) said that the European Medicines Agency (EMA) has recommended approving a medicine from its recently acquired Alexion for a rare, deadly blood... 
Via Benzinga
News headline image
AstraZeneca's Once-Weekly Diabetes Med Wins FDA Nod For Use In Children ↗
The FDA has approved AstraZeneca Plc's (NASDAQ: AZN) Budureon BCise (exenatide extended-release), once-weekly injectable suspension for type 2 diabetes (T2D)... 
Via Benzinga
News headline image
Real-World Data In Canada Shows AstraZeneca's COVID-19 Jab Is Over 80% Effective Against Variants ↗
Results from the Canadian Immunization Research Network (CIRN) showed that one dose of AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine was 82% effective... 
Via Benzinga
News headline image
China Approves AstraZeneca's Imfinzi For Extensive-Stage Small Cell Lung Cancer ↗
National Medical Products Administration of China has approved AstraZeneca plc's (NASDAQ: AZN) Imfinzi (durvalumab) to treat an aggressive type of lung cancer... 
Via Benzinga
News headline image
India Made AstraZeneca's COVID-19 Vaccine Not Eligible For EU Travel, Seeks Resolution: Reuters ↗
Serum Institute of India's (SII) CEO Adar Poonawalla said he was trying to resolve EU travel problems facing Indians inoculated with SII's licensed version of... 
Via Benzinga
News headline image
AstraZeneca Kick-Starts New COVID-19 Variant Vaccine Trial ↗
AstraZeneca Plc (NASDAQ: AZN) has started testing its new COVID vaccine, dubbed AZD2816, a tweaked version using the same platform as its authorized (though not in the... 
Via Benzinga
News headline image
AstraZeneca's Nirsevimab Shows Favorable Safety, Tolerability Profile In Infants At High Risk Of RSV ↗
AstraZeneca Plc (NASDAQ: AZN) announced data from the MEDLEY Phase 2/3 trial evaluating nirsevimab in infants at high risk of respiratory syncytial virus (RSV). The trial... 
Via Benzinga
News headline image
AstraZeneca's Type 2 Diabetes Treatment Shows Clinical Benefit In Adolescents ↗
AstraZeneca Plc (NASDAQ: AZN) has reported results from the Phase 3 trial evaluating exenatide extended-release 2mg in adolescents aged 10–17 years with type... 
Via Benzinga
News headline image
AstraZeneca Unveils 5-Year Survival Data for Imfinzi in Lung Cancer Patients ↗
AstraZeneca Plc’s (NASDAQ: AZN) has announced updated results from the PACIFIC Phase 3 trial of Imfinzi (durvalumab), showing survival benefit at five years... 
Via Benzinga
News headline image
AstraZeneca Seeks Switching COVID-19 Vaccine Production to Catalent Plant: NYT ↗
AstraZeneca Plc (NASDAQ: AZN) is in talks with the U.S. government to shift production of its COVID-19 vaccine from a troubled Emergent BioSolutions Inc’s (... 
Via Benzinga
News headline image
AstraZeneca, Proteros Team Up To Develop Novel Anti-Cancer Medicines ↗
Privately-held Proteros biostructures GmbH has signed an agreement with AstraZeneca Plc (NASDAQ: AZN) to jointly discover and develop novel small... 
Via Benzinga
News headline image
AstraZeneca's Anifrolumab Shows Benefit In Skin, Joint Diseases In Systemic Lupus Erythematosus Patients ↗
AstraZeneca Plc (NASDAQ: AZN) has announced a new posthoc analysis of pooled data from the TULIP Phase 3 clinical trials evaluating anifrolumab in patients with... 
Via Benzinga
News headline image
AstraZeneca's Tagrisso Wins European Approval In Early Lung Cancer ↗
AstraZeneca Plc’s (NASDAQ: AZN) top-selling Tagrisso drug has been approved for use in the European Union to treat patients with a type of early-stage lung... 
Via Benzinga
News headline image
EU Seeks Fines For AstraZeneca Over COVID-19 Vaccine Delays: Reuters ↗
The European Union took on AstraZeneca Plc (NASDAQ: AZN) in a Brussels court and accused it of diverting doses promised to the bloc to other nations. EU’s... 
Via Benzinga
News headline image
Nipro To Provide Fill, Finish Services For AstraZeneca COVID-19 Shots In Japan: Reuters ↗
Japan's Nipro Corporation has signed an agreement to supply AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine in Japan, reports Reuters. Nipro... 
Via Benzinga
News headline image
New Five-Year Data Shows Durable Efficacy Of AstraZeneca's Fasenra For Asthma Treatment ↗
AstraZeneca Plc (NASDAQ: AZN) has announced results from a new integrated analysis, including data from the MELTEMI Phase 3 open-label extension trial, evaluating... 
Via Benzinga
News headline image
Oxford/AstraZeneca Third Booster Strong Enough Against COVID-19 Variants, Study Shows: FT ↗
Oxford University and AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine works well as a third booster shot, according to a study, the Financial Times reported... 
Via Benzinga
News headline image
AstraZeneca's Farxiga Flunks Late-Stage COVID-19 Study ↗
AstraZeneca plc (NASDAQ: AZN) presented detailed data from the DARE-19 Phase 3 trial at the American College of Cardiology, evaluating Farxiga (dapagliflozin... 
Via Benzinga
News headline image
UK Rethinks COVID-19 Antibody Supply Deal With AstraZeneca: Bloomberg ↗
The U.K. government has reconsidered its plan to buy one million doses of AstraZeneca Plc’s (NASDAQ: AZN) anti-SARS-CoV-2 antibody, according to sources... 
Via Benzinga
News headline image
AstraZeneca COVID-19 Vaccine Costs Hit Q1 Earnings; Cancer Meds, Emerging Markets Save The Day ↗
AstraZeneca Plc (NASDAQ: AZN) generated $275 million in revenue from its non-profit COVID-19 vaccine in Q1. Still, it has not been able to keep up with its... 
Via Benzinga
News headline image
I Got My Jab, Here's What Happened, And A Look At Vaccine Stocks ↗
COVID-19 vaccine revenues and profits may be lowballed right now. Ultimately, the underlying companies have very strong business prospects independent of their COVID operations. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.